The remaining HUF 12.96 bln will be placed into profit reserves. The boardʼs dividend proposal was in line with the companyʼs practice of returning one-fourth of IFRS after-tax profit to shareholders. Last year, Richter shareholders approved a HUF 57-per-share dividend on 2013 earnings. CEO Erik Bogsch told shareholders that two of the preparations the company is developing have reached a phase that could lead to the start of their registration within a year.

He said Esmya, Richterʼs unique drug for the treatment of uterine fibroids, would be a “key product” in the companyʼs future. He noted that the European Medicines Agency had recently adopted a positive opinion on long-term treatment with the drug, on the basis of which the European Commission is expected to amend the EU marketing authorization for it within two months.